Pharmacogenetics of Addiction Therapy

David P Graham; Mark J Harding; David A Nielsen

doi:10.1007/978-1-0716-2573-6_16

Pharmacogenetics of Addiction Therapy

Methods Mol Biol. 2022:2547:437-490. doi: 10.1007/978-1-0716-2573-6_16.

Authors

David P Graham¹, Mark J Harding¹, David A Nielsen²

Affiliations

¹ Michael E. DeBakey Veterans Affairs Medical Center, and the Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
² Michael E. DeBakey Veterans Affairs Medical Center, and the Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA. nielsen@bcm.edu.

PMID: 36068473
DOI: 10.1007/978-1-0716-2573-6_16

Abstract

Drug addiction is a serious relapsing disease that has high costs to society and to the individual addicts. Treatment of these addictions is still in its nascency, with only a few examples of successful therapies. Therapeutic response depends upon genetic, biological, social, and environmental components. A role for genetic makeup in the response to treatment has been shown for several addiction pharmacotherapies with response to treatment based on individual genetic makeup. In this chapter, we will discuss the role of genetics in pharmacotherapies, specifically for cocaine, alcohol, and opioid dependences. The continued elucidation of the role of genetics should aid in the development of new treatments and increase the efficacy of existing treatments.

Keywords: Abuse; Addiction; Alcohol; Cocaine; Dependence; Drug; Gene; Opioid; Polymorphism; Therapy.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Behavior, Addictive* / genetics
Behavior, Addictive* / therapy
Cocaine*
Humans
Opioid-Related Disorders* / drug therapy
Opioid-Related Disorders* / genetics
Pharmacogenetics

Substances

Cocaine

Grants and funding

P50 DA018197/DA/NIDA NIH HHS/United States